Have you received REBYOTA to keep recurrent C. diff from coming back? SHARE YOUR STORY>

Flowers on a vine Flowers on a vine Flowers on a vine


Learn about REBYOTA and how it helps keep recurrent C. diff infection from coming back.

REBYOTA (“REE-bye-oh-ta”) is the first and only single-dose, FDA approved microbiome-based treatment to keep recurrent C. diff infection from coming back, after you’ve already taken antibiotics.1

One dose one visit
No Bowel Prep / No Fasting

Learn more about REBYOTA—access Frequently Asked Questions here.

REBYOTA attributes

aCFU=An estimated number of live bacteria in a sample.

Flowers on a vine

This is Freda’s Story

This is Freda’s Story

I just knew that if I had C. diff again, I wasn’t going to survive. But my C. diff didn’t come back after I had my treatment.

- Freda, Clinical Study Patient

Watch Freda’s Story

Most common side effects may include stomach pain, diarrhea, bloating, gas, and nausea.

For more information, please talk to your doctor and see full Prescribing Information. Freda was compensated for her time. Individual results may vary.

Freda’s Story Video: Her Journey to REBYOTA Treatment

Have you also been treated with REBYOTA? SHARE YOUR STORY>

Learn more about recurrent C. diff infection and how to keep it from coming back with REBYOTA.

Download Brochure

In a major clinical study with REBYOTA1,b:



success rate1,c



success rate1,c

Of those patients who saw success with REBYOTAc

~90% stayed free of C. diff at 6 months.2

Most common side effects may include stomach pain (8.9%), diarrhea (7.2%), bloating (3.9%), gas (3.3%), and nausea (3.3%).1
In clinical studies, there were no serious adverse events related to REBYOTA.1

bThe study was conducted in approximately 300 adult patients with recurrent C. diff infection for up to 8 weeks to find out how well REBYOTA
prevented recurrent C. diff infection. Patients in this study first completed treatment with antibiotics.1,2

cSuccess rate indicates no other recurrence of C. diff infection at 8 weeks.2

Flowers on a vine Flowers on a vine

If you’re ready to talk to a doctor, this customized discussion guide is a great way to prepare.

Sign up for more information

Receive additional information and resources to help you through your C. diff infection journey.

What’s your experience with C. diff infection?*(Required)

*Required field.



  1. REBYOTA. Prescribing Information. Parsippany, NJ: Ferring Pharmaceuticals Inc; 2022.
  2. Khanna S, Assi M, Lee C, et al. Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double blind, placebo controlled trial with a Bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection. Drugs. 2022;82(15):1527-1538.

Please see Important Safety Information and full Prescribing Information


REBYOTA (fecal microbiota, live – jslm) is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection.
Limitation of Use
REBYOTA is not indicated for the treatment of C. diff infection.

Important Safety Information

  • You should not receive REBYOTA if you have a history of a severe allergic reaction (e.g., anaphylaxis) to REBYOTA or any of its components.
  • You should report to your doctor any infection you think you may have acquired after administration.
  • REBYOTA may contain food allergens.
  • Most common side effects may include stomach pain (8.9%), diarrhea (7.2%), bloating (3.9%), gas (3.3%), and nausea (3.3%).
  • REBYOTA has not been studied in patients below 18 years of age.
  • Clinical studies did not determine if adults 65 years of age and older responded differently than younger adults.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088.

Please click to see the full Prescribing Information

You are leaving REBYOTA.com

The link you have selected will direct you to a site or resource outside of our website.
Thank you.